XML 91 R76.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration, License, and Other Agreements - European and Other Territories (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Oct. 31, 2015
Collaboration, License, Promotion and Other Commercial Agreements                        
Revenue $ 90,545 $ 91,592 $ 94,396 $ 74,877 $ 117,553 $ 113,739 $ 107,382 $ 104,061 $ 351,410 $ 442,735 $ 410,596  
AbbVie Plc                        
Collaboration, License, Promotion and Other Commercial Agreements                        
Collaborative arrangement, royalty, net sales of products containing active ingredient, period following first commercial sale                 5 years      
Collaborative arrangements revenue                        
Collaboration, License, Promotion and Other Commercial Agreements                        
Revenue                 $ 351,410 442,735 410,596  
Collaborative arrangement, collaboration and license agreements | AbbVie Plc | Europe and Other                        
Collaboration, License, Promotion and Other Commercial Agreements                        
Revenue                 3,236 2,779 2,444  
Royalty | AbbVie Plc | Europe and Other                        
Collaboration, License, Promotion and Other Commercial Agreements                        
Revenue                 $ 3,200 $ 2,800 $ 2,400  
License | AbbVie Plc                        
Collaboration, License, Promotion and Other Commercial Agreements                        
Remaining milestone payment due upon the amendment to the license agreement                       $ 42,500